BioVest International, Inc. operates as a biotechnology company, focusing on production and contract manufacturing of biologic drugs and products from small through commercial scale in the United States. The company manufactures cell culture products, such as mammalian and insect cells, recombinant and secreted proteins, and monoclonal antibodies, as well as provides related services in developing cell production process protocols, cell line optimization, cell culture production optimization, and media evaluation services. It operates a National Cell Culture Center, which provides customized cell culture services for basic research laboratories. The company also specializes in hollow fiber perfusion instruments, including Primer HF, miniMax, Maximizer, and XCellerator products, which are used for the production of quantities of cell culture products. In addition, BioVest International sells hollow fiber bioreactors, culture ware, tubing sets, and other disposable products. Further, it is developing a therapeutic vaccine known as, Biovaxid for treatment of the follicular form of nonHodgkin’s lymphoma in collaboration with the National Cancer Institute, which is in Phase III clinical trial. The company’s customers include biopharmaceutical and biotech companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. BioVest International was incorporated in 1981 under the name Endotronics, Inc. and changed its name to Cellex Biosciences, Inc. in 1993. Further, the company changed its name to Biovest International, Inc. in 2001 and also changed its state of incorporation from Minnesota to Delaware. The company is headquartered in Minneapolis, Minnesota. BioVest International, Inc. is a subsidiary of Accentia BioPharmaceuticals, Inc., as of September 30, 2004.